PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT • 2.1 Preface • 2.2 Preface • 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 04: MARKET SIZING • Market definition • Market sizing 2018 • Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition • PART 06: PIPELINE PART 07: MARKET SEGMENTATION BY TYPE • Market segmentation by type • Comparison by type • Systemic hypertension - Market size and forecast 2018-2023 • Pulmonary hypertension - Market size and forecast 2018-2023 • Market opportunity by type PART 08: CUSTOMER LANDSCAPE PART 09: GEOGRAPHIC LANDSCAPE • Geographic segmentation • Geographic comparison • North America - Market size and forecast 2018-2023 • Europe - Market size and forecast 2018-2023 • Asia - Market size and forecast 2018-2023 • ROW - Market size and forecast 2018-2023 • Key leading countries • Market opportunity PART 10: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 11: MARKET TRENDS PART 12: VENDOR LANDSCAPE • Overview • Landscape disruption • Competitive scenario PART 13: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • AstraZeneca • Johnson & Johnson Services, Inc. • Merck & Co., Inc. • Novartis AG • Pfizer Inc. PART 14: APPENDIX • Research methodology • List of abbreviations   Exhibit 01: Global pharmaceuticals market Exhibit 02: Segments of global pharmaceuticals market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Market definition - Inclusions and exclusions checklist Exhibit 06: Market size 2018 Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 08: Global market: Year-over-year growth 2019-2023 (%) Exhibit 09: Five forces analysis 2018 Exhibit 10: Five forces analysis 2023 Exhibit 11: Bargaining power of buyers Exhibit 12: Bargaining power of suppliers Exhibit 13: Threat of new entrants Exhibit 14: Threat of substitutes Exhibit 15: Threat of rivalry Exhibit 16: Market condition - Five forces 2018 Exhibit 17: Global antihypertensive drugs market pipeline: Overview Exhibit 18: Phase III pipeline molecules: Overview Exhibit 19: Type - Market share 2018-2023 (%) Exhibit 20: Comparison by type Exhibit 21: Systemic hypertension - Market size and forecast 2018-2023 ($ millions) Exhibit 22: Systemic hypertension - Year-over-year growth 2019-2023 (%) Exhibit 23: Pulmonary hypertension - Market size and forecast 2018-2023 ($ millions) Exhibit 24: Some of the drugs available for treatment of pulmonary hypertension Exhibit 25: Pulmonary hypertension - Year-over-year growth 2019-2023 (%) Exhibit 26: Market opportunity by type Exhibit 27: Customer landscape Exhibit 28: Market share by geography 2018-2023 (%) Exhibit 29: Geographic comparison Exhibit 30: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 31: North America - Year-over-year growth 2019-2023 (%) Exhibit 32: Top 3 countries in North America Exhibit 33: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 34: Europe - Year-over-year growth 2019-2023 (%) Exhibit 35: Top 3 countries in Europe Exhibit 36: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 37: Asia - Year-over-year growth 2019-2023 (%) Exhibit 38: Top 3 countries in Asia Exhibit 39: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 40: ROW - Year-over-year growth 2019-2023 (%) Exhibit 41: Top 3 countries in ROW Exhibit 42: Key leading countries Exhibit 43: Market opportunity Exhibit 44: Available drugs for treatment of hypertension: Overview Exhibit 45: Generic drugs that received approval from US FDA for treatment of hypertension since 2016: Overview Exhibit 46: Impact of drivers and challenges Exhibit 47: Vendor landscape Exhibit 48: Landscape disruption Exhibit 49: Vendors covered Exhibit 50: Vendor classification Exhibit 51: Market positioning of vendors Exhibit 52: AstraZeneca - Vendor overview Exhibit 53: AstraZeneca - Business segments Exhibit 54: AstraZeneca - Organizational developments Exhibit 55: AstraZeneca - Geographic focus Exhibit 56: AstraZeneca - Key offerings Exhibit 57: AstraZeneca - Key customers Exhibit 58: Johnson & Johnson Services, Inc. - Vendor overview Exhibit 59: Johnson & Johnson Services, Inc. - Business segments Exhibit 60: Johnson & Johnson Services, Inc. - Organizational developments Exhibit 61: Johnson & Johnson Services, Inc. - Geographic focus Exhibit 62: Johnson & Johnson Services, Inc. - Segment focus Exhibit 63: Johnson & Johnson Services, Inc. - Key offerings Exhibit 64: Johnson & Johnson Services, Inc. - Key customers Exhibit 65: Merck & Co., Inc. - Vendor overview Exhibit 66: Merck & Co., Inc. - Business segments Exhibit 67: Merck & Co., Inc. - Organizational developments Exhibit 68: Merck & Co., Inc. - Geographic focus Exhibit 69: Merck & Co., Inc. - Segment focus Exhibit 70: Merck & Co., Inc. - Key offerings Exhibit 71: Merck & Co., Inc. - Key customers Exhibit 72: Novartis AG - Vendor overview Exhibit 73: Novartis AG - Business segments Exhibit 74: Novartis AG - Organizational developments Exhibit 75: Novartis AG - Geographic focus Exhibit 76: Novartis AG - Segment focus Exhibit 77: Novartis AG - Key offerings Exhibit 78: Novartis AG - Key customers Exhibit 79: Pfizer Inc. - Vendor overview Exhibit 80: Pfizer Inc. - Business segments Exhibit 81: Pfizer Inc. - Organizational developments Exhibit 82: Pfizer Inc. - Geographic focus Exhibit 83: Pfizer Inc. - Segment focus Exhibit 84: Pfizer Inc. - Key offerings Exhibit 85: Pfizer Inc. - Key customers Exhibit 86: Validation techniques employed for market sizing Exhibit 87: List of abbreviations

AstraZeneca Johnson & Johnson Services, Inc. Merck & Co., Inc. Novartis AG Pfizer Inc.